Percheron Therapeutics Limited · ASX:PER
Percheron Therapeutics — Investor Presentation (September 2026)
14 slides from Percheron Therapeutics's investor presentation, Sep 1, 2026
Slide 1: Percheron Therapeutics Corporate Presentation announcement
PERCHERON THERAPEUTICS CORPORATE PRESENTATION Melbourne, Australia – 1 September 2026: Percheron Therapeutics Limited (ASX: PER) (‘the Company’), an international biotechnology company focused on the development of novel therapies for oncology and rare diseases, is pleased to provide shareholders wi
Slide 2: Advancing a Next Generation Immune Checkpoint Inhibitor into Blood Cancers
For personal use only Advancing a Next Generation Immune Checkpoint Inhibitor into Blood Cancers Investor Update September 2026 www.PercheronTx.com ASX: PER | US OTC: PERCF
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions such as the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and may be accompanied by words such
Slide 4: Executive Summary
Executive Summary • Percheron has entered into an agreement with Vanderbilt Health (VH) to conduct a multi-centre clinical trial of HMBD-002 in patients with acute myeloid leukaemia (AML) For personal use only • AML is the most common form of leukaemia, with about 20,000 patients diagnosed annually
Slide 5: Percheron is developing HMBD-002, a novel, mid-clinical-stage, immuno-oncology therapy
Percheron is developing HMBD-002, a novel, mid-clinical-stage, immuno-oncology therapy with applicability to multiple forms of cancer and high combination potential THE SCIENCE THE COMPANY THE OPPORTUNIT Y For personal use only Percheron is developing HMBD-002, Percheron is listed on the ASX (ASX: P
Slide 6: Immune checkpoint inhibitors such as HMBD-002 reactivate the immune response
Immune checkpoint inhibitors such as HMBD-002 work by reactivating the body’s immune response so that it can attack the tumour For personal use only Immune cells Cancer cells HMBD-002 • Ordinarily, our immune system • Immune checkpoint inhibitors such as • Removal of the inhibitory signals • In addi
Slide 7: HMBD-002 is arguably the most advanced VISTA antibody in clinical development
INDICATIVE HMBD-002 is arguably the most advanced VISTA antibody in clinical development, and likely the only active member of the IgG4 class Program HMBD-002 CI-8993 JNJ-61610588 SNS-101 W0180 For personal use only Company In general, IgG1 antibodies activate antibody-dependent cellular cytotoxicit
Slide 8: Acute myeloid leukaemia (AML) is the most common form of leukaemia in adults
Acute myeloid leukaemia (AML) is the most common form of leukaemia in adults Pathology Clinical Picture Standard of Care For personal use only • AML is a cancer of the progenitor cells • Common symptoms of AML include • First-line treatment is with intensive which ordinarily give rise to myeloid fat
Slide 9: VISTA is a highly relevant and attractive target for treatment of AML
VISTA is a highly relevant and attractive target for treatment of AML VISTA is highly expressed VISTA expression correlates with Blocking VISTA improves clinical For personal use only on AML blasts survival in AML models outcome in AML models Healthy Donor AML Control Anti-VISTA antibody VISTA High
Slide 10: The study is planned in two stages, under an open label design
PRELIMINARY The study is planned to be conducted in two stages, under an open label design For personal use only Stage 1 Stage 2 Venetoclax Confirm dose of Identify signals of • Inhibits Bcl-2 protein, implicated in HMBD-002 in potential efficacy several blood cancers combination with • Discovered a
Slide 11: The Percheron Board and Management Team
The Percheron Board and Management Team bring extensive international experience in drug development, commercialisation, and partnering Dr Charmaine Gittleson * Dr Michael Baker Dr Gil Price Dr James Garner Non-Executive Chair of the Chief Executive Officer Non-Executive Director Non-Executive Direc
Slide 12: Percheron benefits from an ultra-lean operating model
AS AT 30 JUN 2026 Percheron benefits from an ultra-lean operating model, with the majority of cash outlays being applied directly to R&D Corporate Fundamentals (as at 30 June 2026) Share Price (AU$) Volume For personal use only $0.010 100 Market Capitalisation: AU$ 4.6M Millions Primary Listing: ASX
Slide 13: Percheron is focused on moving its pipeline forward expeditiously
PRELIMINARY Percheron is focused on moving its pipeline forward expeditiously, with potential for rich, value-generating news flow over FY2026 CY2026 For personal use only Presentation of data at scientific conferences 1H CY2026 ✓ Grant of provisional international nonproprietary name (INN) for HMBD
Slide 14: For personal use only
For personal use only info@PercheronTx.com www.PercheronTx.com
Percheron Therapeutics — Investor Presentation (September 2026) on 6ix